Key result
Liberal GP IIb/IIIa use shows no reflow benefit but is linked to ~185% higher bleeding risk.
Why the study?
The ongoing role and safety of GpIIb-IIIa-inhibitors during primary PCI for STEMI in combination with newer P2Y12-inhibitors remains unclear.
Does a liberal up-front glycoprotein IIb-IIIa antagonist strategy improve ischemic outcomes or increase bleeding compared to a conservative bail-out strategy in STEMI patients undergoing primary PCI?
Cohort (n=459)
Yes
Does a liberal up-front glycoprotein IIb-IIIa antagonist strategy improve ischemic outcomes or increase bleeding compared to a conservative bail-out strategy in STEMI patients undergoing primary PCI?
In contemporary STEMI management, a conservative bail-out strategy for glycoprotein IIb-IIIa antagonists reduces clinically relevant bleeding without increasing ischemic complications compared to a liberal up-front strategy.
Answers are grounded in this paper and cite their sources.
Supports conservative bail-out glycoprotein IIb-IIIa use in STEMI PCI to limit bleeding; leaves open randomized confirmation.
Background While the efficacy of GpIIb-IIIa-inhibitors during primary PCI (pPCI) for ST-elevated myocardial infarction (STEMI) has previously been demonstrated, its ongoing role and safety in combination with newer P2Y12-inhibitors is unclear. We therefore sought to compare outcomes between two centers with divergent approaches to the use of GpIIbIIIa antagonists in pPCI. Methods We performed a retrospective chart review of all-comer STEMI patients treated with pPCI at two high-volume Montreal academic tertiary care centers. One center tended to use GpIIb-IIIa-inhibitors up-front in a large proportion of patients (liberal strategy) and the other preferring a bail-out approach (conservative strategy). Baseline patient characteristics and procedural data were compared between the two groups. The main efficacy outcome was rate of no-reflow/slow-reflow and the main safety outcome was BARC ³ 2 bleeding events. Results A total of 459 patients were included, of whom 167 (36.5%) were exposed to a GpIIb-IIIa-antagonist. There was a significant overall difference in use of GpIIb-IIIa-antagonist between the two centers (60.5% vs 16.1%, p<0.01) Rate of no-reflow/slow-reflow was similar between groups (2.6% vs 1.4%, p=0.22). In-hospital rates of unplanned revascularization, stroke and death were aslo not different between groups. Use of a liberal GpIIb-IIIa-antagonist strategy was associated with a higher risk of bleeding (OR 3.16, p <0.01), which persisted after adjustment for covariables (adjusted OR 2.85, p <0.01). Conclusions In this contemporary retrospective cohort, a conservative GpIIb-IIIa-antagonist strategy was associated with a lower incidence of clinically relevant bleeding without any signal for an increase in no-reflow/slow-reflow or ischemic clinical events.
No takes yet. Share an insight, caveat, or question.
Potter et al. (2024) conducted a cohort in ST-Elevation Myocardial Infarction (STEMI) (n=459). Liberal Glycoprotein IIb-IIIa antagonist strategy vs. Conservative Glycoprotein IIb-IIIa antagonist strategy was evaluated on Rate of no-reflow/slow-reflow during pPCI (OR 1.63, 95% CI 0.43-8.16, p=0.47). A liberal glycoprotein IIb-IIIa antagonist strategy did not reduce no-reflow/slow-reflow compared to a conservative strategy but increased BARC ≥2 bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: